Your browser doesn't support javascript.
A Dual-Antigen Enzyme-Linked Immunosorbent Assay Allows the Assessment of Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Seroprevalence in a Low-Transmission Setting.
Hicks, Sarah M; Pohl, Kai; Neeman, Teresa; McNamara, Hayley A; Parsons, Kate M; He, Jin-Shu; Ali, Sidra A; Nazir, Samina; Rowntree, Louise C; Nguyen, Thi H O; Kedzierska, Katherine; Doolan, Denise L; Vinuesa, Carola G; Cook, Matthew C; Coatsworth, Nicholas; Myles, Paul S; Kurth, Florian; Sander, Leif E; Mann, Graham J; Gruen, Russell L; George, Amee J; Gardiner, Elizabeth E; Cockburn, Ian A.
  • Hicks SM; Australian Cancer Research Foundation Department of Cancer Biology and Therapeutics, John Curtin School of Medical Research, The Australian National University, Canberra, Australia.
  • Pohl K; Department of Immunology and Infectious Disease, John Curtin School of Medical Research, The Australian National University, Canberra, Australia.
  • Neeman T; Department of Infectious Diseases and Respiratory Medicine, Charité, Universitatsmedizin Berlin, Berlin, Germany.
  • McNamara HA; Biological Data Science Institute, John Curtin School of Medical Research, The Australian National University, Canberra, Australia.
  • Parsons KM; Department of Immunology and Infectious Disease, John Curtin School of Medical Research, The Australian National University, Canberra, Australia.
  • He JS; Australian National University Centre for Therapeutic Discovery, The Australian National University, Canberra, Australia.
  • Ali SA; Australian National University Centre for Therapeutic Discovery, The Australian National University, Canberra, Australia.
  • Nazir S; Australian Cancer Research Foundation Department of Cancer Biology and Therapeutics, John Curtin School of Medical Research, The Australian National University, Canberra, Australia.
  • Rowntree LC; Australian Cancer Research Foundation Department of Cancer Biology and Therapeutics, John Curtin School of Medical Research, The Australian National University, Canberra, Australia.
  • Nguyen THO; Department of Microbiology and Immunology, Peter Doherty Institute, University of Melbourne, Melbourne, Australia.
  • Kedzierska K; Department of Microbiology and Immunology, Peter Doherty Institute, University of Melbourne, Melbourne, Australia.
  • Doolan DL; Department of Microbiology and Immunology, Peter Doherty Institute, University of Melbourne, Melbourne, Australia.
  • Vinuesa CG; Centre for Molecular Therapeutics, Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, Australia.
  • Cook MC; Department of Immunology and Infectious Disease, John Curtin School of Medical Research, The Australian National University, Canberra, Australia.
  • Coatsworth N; China Australia Centre for Personalised Immunology, Shanghai Renji Hospital, Jiaotong University, Shanghai, China.
  • Myles PS; Department of Immunology Canberra Hospital, Canberra, Australia.
  • Kurth F; Department of Immunology and Infectious Disease, John Curtin School of Medical Research, The Australian National University, Canberra, Australia.
  • Sander LE; Department of Immunology Canberra Hospital, Canberra, Australia.
  • Mann GJ; ANU Medical School, Australian National University, Canberra, Australia.
  • Gruen RL; The Canberra Hospital, Infectious Diseases, Canberra, Australia.
  • George AJ; Department of Anaesthesiology and Perioperative Medicine, Alfred Hospital, Melbourne, Australia.
  • Gardiner EE; Department of Anaesthesiology and Perioperative Medicine, Monash University, Melbourne, Australia.
  • Cockburn IA; Department of Infectious Diseases and Respiratory Medicine, Charité, Universitatsmedizin Berlin, Berlin, Germany.
J Infect Dis ; 223(1): 10-14, 2021 01 04.
Article in English | MEDLINE | ID: covidwho-1066339
ABSTRACT
Estimates of seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies have been hampered by inadequate assay sensitivity and specificity. Using an enzyme-linked immunosorbent assay-based approach that combines data about immunoglobulin G responses to both the nucleocapsid and spike receptor binding domain antigens, we show that excellent sensitivity and specificity can be achieved. We used this assay to assess the frequency of virus-specific antibodies in a cohort of elective surgery patients in Australia and estimated seroprevalence in Australia to be 0.28% (95% Confidence Interval, 0-1.15%). These data confirm the low level of transmission of SARS-CoV-2 in Australia before July 2020 and validate the specificity of our assay.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Enzyme-Linked Immunosorbent Assay / Seroepidemiologic Studies / COVID-19 / Antibodies, Viral Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Limits: Humans Country/Region as subject: Oceania Language: English Journal: J Infect Dis Year: 2021 Document Type: Article Affiliation country: Infdis

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Enzyme-Linked Immunosorbent Assay / Seroepidemiologic Studies / COVID-19 / Antibodies, Viral Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Limits: Humans Country/Region as subject: Oceania Language: English Journal: J Infect Dis Year: 2021 Document Type: Article Affiliation country: Infdis